Interestingly, a high pCR rate was also evident in patients with low ER expression (1–9%), irrespective of HER2 protein expression and TIL levels, aligning with the classification of low-ER-expression, HER2- negative breast cancer as a triple-negative breast cancer [32,33,34,35]. Here, ERBB2 is linked to triple-negative breast carcinoma.